"we now have a world class institute managing" — we had this in the first try as well. The error wasn't in choosing a bad CRO, it was in choosing a CRO with the wrong background and not realising that the difference is important.
"updated algorithms" — they're not updated. The application has a better user interface, and some added validation features to ensure that the collected data is of usable quality. But the algorithm is the same.
On a broader note, I don't expect the current pip to hold. This announcement doesn't really alter the risk profile. There was never any significant risk that the trials wouldn't begin. I believe that significant reduction in risk will be perceived from:
1) release of some good double-blind results, and
2) the first Smartcough-C-2 update if they can release good data quality monitoring results.
I would expect significant and sustained re-rates from each of these events.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Enrols First Patient in SMARTCOUGH-C-2 Study
Ann: ResApp Enrols First Patient in SMARTCOUGH-C-2 Study, page-14
-
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
Add RAP (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable